THE IMPACT OF LIPID-LOWERING THERAPIES ON THE MANAGEMENT OF DYSLIPIDEMIA AND THE PREVENTION OF CARDIOVASCULAR EVENTS
Lipid-lowering therapies, such as PCSK9 inhibitors and bempedoic acid, are essential in the treatment of dyslipidemia, especially for patients who do not reach their LDL-C targets with statins. PCSK9 inhibitors can reduce LDL-C levels by up to 60% and have shown efficacy in preventing cardiovascular events in high-risk populations. However, their high cost limits access, generating debate about cost-effectiveness, especially in developing countries. Bempedoic acid offers an alternative for those who cannot tolerate statins, but its efficacy in cardiovascular events still needs more data. Long-term safety and affordability are key concerns as these therapies evolve.
THE IMPACT OF LIPID-LOWERING THERAPIES ON THE MANAGEMENT OF DYSLIPIDEMIA AND THE PREVENTION OF CARDIOVASCULAR EVENTS
-
DOI: https://doi.org/10.22533/at.ed.1594952423105
-
Palavras-chave: Dyslipidemia. Hypoglycemic agents. Cardiovascular events. Prevention.
-
Keywords: Dyslipidemia. Hypoglycemic agents. Cardiovascular events. Prevention.
-
Abstract:
Lipid-lowering therapies, such as PCSK9 inhibitors and bempedoic acid, are essential in the treatment of dyslipidemia, especially for patients who do not reach their LDL-C targets with statins. PCSK9 inhibitors can reduce LDL-C levels by up to 60% and have shown efficacy in preventing cardiovascular events in high-risk populations. However, their high cost limits access, generating debate about cost-effectiveness, especially in developing countries. Bempedoic acid offers an alternative for those who cannot tolerate statins, but its efficacy in cardiovascular events still needs more data. Long-term safety and affordability are key concerns as these therapies evolve.
- Jhony Lucas Inácio de Almeida
- Giovana Elisa Rosa Galiassi
- Gabriel Nogueira Zuntini
- Mikaella Dal Piva
- Nicolli Zamo Ortolan
